Development of Micro-Electrode Array Based Tests for Neurotoxicity: Assessment of Interlaboratory Reproducibility with Neuroactive Chemicals

Abstract

Neuronal assemblies within the nervous system produce electrical activity that can be recorded in terms of action potential patterns. Such patterns provide a sensitive endpoint to detect effects of a variety of chemical and physical perturbations. They are a function of synaptic changes and do not necessarily involve structural alterations. In vitro neuronal networks (NNs) grown on micro-electrode arrays (MEAs) respond to neuroactive substances as well as the in vivo brain. As such, they constitute a valuable tool for investigating changes in the electrophysiological activity of the neurons in response to chemical exposures. However, the reproducibility of NN responses to chemical exposure has not been systematically documented. To this purpose six independent laboratories (in Europe and in USA) evaluated the response to the same pharmacological compounds (Fluoxetine, Muscimol, and Verapamil) in primary neuronal cultures. Common standardization principles and acceptance criteria for the quality of the cultures have been established to compare the obtained results. These studies involved more than 100 experiments before the final conclusions have been drawn that MEA technology has a potential for standard in vitro neurotoxicity/neuropharmacology evaluation. The obtained results show good intra- and inter-laboratory reproducibility of the responses. The consistent inhibitory effects of the compounds were observed in all the laboratories with the 50% Inhibiting Concentrations (IC50s) ranging from: (mean ± SEM, in μM) 1.53 ± 0.17 to 5.4 ± 0.7 (n = 35) for Fluoxetine, 0.16 ± 0.03 to 0.38 ± 0.16 μM (n = 35) for Muscimol, and 2.68 ± 0.32 to 5.23 ± 1.7 (n = 32) for Verapamil. The outcome of this study indicates that the MEA approach is a robust tool leading to reproducible results. The future direction will be to extend the set of testing compounds and to propose the MEA approach as a standard screen for identification and prioritization of chemicals with neurotoxicity potential.

d-Methionine protects against cisplatin-induced neurotoxicity in cortical networks

“…The in vitro environment allows precise, reproducible pharmacological manipulations with no homeostatic interference from other organs. Morphological changes of neurons in the networks can be correlated optically with electrophysiological changes, and network deterioration can be followed systematically, providing a platform for rapid, quantitative screening of new chemical and pharmaceutical compounds (Johnstone et al, 2010;Novellino et al, 2011;Wu et al, 2011). Mice have been extensively used as the mammalian animal model in physiological and pharmacological experiments.…”

A Multifaceted GABAAReceptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude)

“…This technology has previously been used extensively for neurotoxicity studies (Gramowski et al, 2006b;Johnstone et al, 2010;Novellino et al, 2011) but also for functional phenotypic screening of drugs (Gramowski et al, 2004(Gramowski et al, , 2006aParenti et al, 2013). The 204 activitydescribing parameters calculated based on the spike trains from these recordings can be divided into four categories.…”

Adverse Outcome Pathway on chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities

“…MEAs can be applied in high throughput platforms to facilitate screening of numerous chemical compounds . Using selective agonists and antagonists of different classes of receptors their response can be evaluated in a quantitative manner (Novellino et al, 2011;Hogberg et al, 2011). Patch clamping technique can also be used to measure neuronal network activity.…”